G Merlini

Summary

Affiliation: University of Pavia
Country: Italy

Publications

  1. doi request reprint Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities
    Andrew Davenport
    UCL Centre for Nephrology, Royal Free Hospital, London, UK
    Nephrol Dial Transplant 27:3713-8. 2012
  2. doi request reprint Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study
    Laura Obici
    Amyloid Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy
    Amyloid 19:34-6. 2012
  3. ncbi request reprint The Pavia approach to clinical protein analysis
    G Merlini
    Biotechnology Research Laboratories, University Hospital IRCCS Policlinico San Matteo, Pavia, Italy
    Clin Chem Lab Med 39:1025-8. 2001
  4. ncbi request reprint Mechanisms of renal damage in plasma cell dyscrasias: an overview
    Giampaolo Merlini
    Amyloidosis Center, Biotechnology Research Laboratories, Fondazione, IRCCS Policlinico San Matteo and Department of Biochemistry, University of Pavia, Pavia, Italy
    Contrib Nephrol 153:66-86. 2007
  5. doi request reprint Standardizing plasma protein measurements worldwide: a challenging enterprise
    Giampaolo Merlini
    Biotechnology Research Laboratories, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Department of Biochemistry, University of Pavia, Pavia, Italy
    Clin Chem Lab Med 48:1567-75. 2010
  6. ncbi request reprint Molecular mechanisms of amyloidosis
    Giampaolo Merlini
    Amyloid Center, Biotechnology Research Laboratory, University Hospital IRCCS Policlinico San Matteo, Pavia, Italy
    N Engl J Med 349:583-96. 2003
  7. ncbi request reprint Protein aggregation
    G Merlini
    Biotechnology Research Laboratories, University Hospital IRCCS Policlinico San Matteo, Pavia, Italy
    Clin Chem Lab Med 39:1065-75. 2001
  8. ncbi request reprint Dangerous small B-cell clones
    Giampaolo Merlini
    Amyloid Center, Biotechnology Research Laboratories, Foundation IRCCS Policlinico San Matteo, Piazzale Golgi 2, 27100 Pavia, Italy
    Blood 108:2520-30. 2006
  9. pmc Amyloidosis: pathogenesis and new therapeutic options
    Giampaolo Merlini
    Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, University of Pavia, P le Golgi, 19, 27100 Pavia, Italy
    J Clin Oncol 29:1924-33. 2011
  10. ncbi request reprint A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis
    G Palladini
    Internal Medicine and Medical Oncology, and Biotechnology Research Laboratories, Policlinico San Matteo, Pavia, Italy
    Br J Haematol 113:1044-6. 2001

Detail Information

Publications87

  1. doi request reprint Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities
    Andrew Davenport
    UCL Centre for Nephrology, Royal Free Hospital, London, UK
    Nephrol Dial Transplant 27:3713-8. 2012
    ..Basic research findings have led to the design of targeted drugs that prevented the functional manifestations of acute kidney injury in animal models. There is now hope to prevent the renal damage in patients with MM...
  2. doi request reprint Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study
    Laura Obici
    Amyloid Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy
    Amyloid 19:34-6. 2012
    ..These preliminary data indicate that the combination of Doxy-TUDCA stabilizes the disease for at least 1 year in the majority of patients with an acceptable toxicity profile...
  3. ncbi request reprint The Pavia approach to clinical protein analysis
    G Merlini
    Biotechnology Research Laboratories, University Hospital IRCCS Policlinico San Matteo, Pavia, Italy
    Clin Chem Lab Med 39:1025-8. 2001
    ..This labor-intensive approach requires skills in the performance of protein analysis and in the interpretation/referral phase, as well as close communication with the attending physician...
  4. ncbi request reprint Mechanisms of renal damage in plasma cell dyscrasias: an overview
    Giampaolo Merlini
    Amyloidosis Center, Biotechnology Research Laboratories, Fondazione, IRCCS Policlinico San Matteo and Department of Biochemistry, University of Pavia, Pavia, Italy
    Contrib Nephrol 153:66-86. 2007
    ..In patients with known plasma cell dyscrasia, the recognition of these patterns of renal injury should lead to appropriate therapeutic intervention...
  5. doi request reprint Standardizing plasma protein measurements worldwide: a challenging enterprise
    Giampaolo Merlini
    Biotechnology Research Laboratories, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Department of Biochemistry, University of Pavia, Pavia, Italy
    Clin Chem Lab Med 48:1567-75. 2010
    ..Plasma protein reference materials have had a substantial impact in improving the harmonization of patient protein results that should translate into better patient care...
  6. ncbi request reprint Molecular mechanisms of amyloidosis
    Giampaolo Merlini
    Amyloid Center, Biotechnology Research Laboratory, University Hospital IRCCS Policlinico San Matteo, Pavia, Italy
    N Engl J Med 349:583-96. 2003
  7. ncbi request reprint Protein aggregation
    G Merlini
    Biotechnology Research Laboratories, University Hospital IRCCS Policlinico San Matteo, Pavia, Italy
    Clin Chem Lab Med 39:1065-75. 2001
    ..As different molecular mechanisms are involved in the formation of the various forms of protein aggregates, the laboratory diagnostic approach remains frequently elusive...
  8. ncbi request reprint Dangerous small B-cell clones
    Giampaolo Merlini
    Amyloid Center, Biotechnology Research Laboratories, Foundation IRCCS Policlinico San Matteo, Piazzale Golgi 2, 27100 Pavia, Italy
    Blood 108:2520-30. 2006
    ..Although the treatment of these conditions is not optimal, significant advances have been made, improving the duration and quality of life...
  9. pmc Amyloidosis: pathogenesis and new therapeutic options
    Giampaolo Merlini
    Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, University of Pavia, P le Golgi, 19, 27100 Pavia, Italy
    J Clin Oncol 29:1924-33. 2011
    ..Advances in basic research have led to the identification of new drug targets and therapeutic approaches, which will be integrated with chemotherapy in the future...
  10. ncbi request reprint A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis
    G Palladini
    Internal Medicine and Medical Oncology, and Biotechnology Research Laboratories, Policlinico San Matteo, Pavia, Italy
    Br J Haematol 113:1044-6. 2001
    ..This regimen may be considered front-line therapy when autologous stem cell transplantation is not feasible and when a rapid response is particularly important...
  11. pmc Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure
    P Mangione
    Department of Biochemistry, University of Pavia, 27100 Pavia, Italy
    Protein Sci 10:187-99. 2001
    ..The addition of phospholipids to the monomeric form induces the formation of some helical structure, thought most likely to occur at the C-terminal end of the polypeptide...
  12. ncbi request reprint Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis
    Giovanni Palladini
    Department of Internal Medicine, University Hospital IRCCS Policlinico San Matteo University of Pavia, Pavia, Italy
    Circulation 107:2440-5. 2003
    ..We investigated the prognostic value of NT-proBNP and its utility in monitoring amyloid heart dysfunction...
  13. ncbi request reprint Biological features of the clone involved in primary amyloidosis (AL)
    V Perfetti
    Department of Internal Medicine, IRCCS Policlinico S Matteo, University of Pavia, Italy
    Leukemia 15:195-202. 2001
    ..Knowledge of the pathobiology of the underlying B cell clone is of primary importance for the design and optimization of therapeutic strategies...
  14. ncbi request reprint Holter monitoring in AL amyloidosis: prognostic implications
    G Palladini
    Department of Internal Medicine and Medical Oncology, University of Pavia, Italy
    Pacing Clin Electrophysiol 24:1228-33. 2001
    ..The presence of couplets correlated with sudden death. Holter monitoring may contribute to assessing the prognosis of patients with AL amyloidosis...
  15. ncbi request reprint Clotting alterations in primary systemic amyloidosis
    G Gamba
    Istituto di Medicina Interna e Oncologia Medica, IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Haematologica 85:289-92. 2000
    ..This investigation was aimed at defining the prevalence of clotting abnormalities and their clinical manifestations in patients with AL...
  16. pmc The new apolipoprotein A-I variant leu(174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide
    L Obici
    Biotechnology Research Laboratories, Institute of Human Pathology, Division of Cardiology, IRCCS Policlinico San Matteo, Pavia, Italy
    Am J Pathol 155:695-702. 1999
    ....
  17. doi request reprint Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide
    Giovanni Palladini
    Biotechnology Research Laboratories, Center for Amyloidosis, Department of Biochemistry, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Matteo and University of Pavia, Piazzale Golgi, 19, 27100 Pavia, Italy
    Ann Hematol 88:347-50. 2009
    ..Treatment with MTD is feasible in patients with advanced cardiac AL amyloidosis and effective in subjects with preserved systolic function...
  18. ncbi request reprint Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO)
    Giovanni Barosi
    Laboratorio di Epidemiologia Clinica, IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 89:717-41. 2004
    ....
  19. ncbi request reprint Bone marrow amyloidosis
    Rosangela Invernizzi
    Department of Internal Medicine, University of Pavia and IRCCS Policlinico S Matteo, Pavia, Italy
    Haematologica 91:EIM01. 2006
  20. ncbi request reprint Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis
    Stefano Ghio
    Division of Cardiology, Fondazione IRCCS Policlinico S Matteo and University of Pavia, 27100 Pavia, Italy
    Eur J Heart Fail 9:808-13. 2007
    ..Patients with AL amyloidosis often present with signs of congestive heart failure...
  21. ncbi request reprint Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis 1
    Riccardo Caccialanza
    Nutrition and Dietetics Service and the Department of Health Sciences, Section of Human Nutrition and Dietetics, University of Pavia, Pavia, Italy
    Am J Clin Nutr 83:350-4. 2006
    ..Maintenance of a good nutritional status is associated with prolonged survival in many chronic diseases. To date, the nutritional status of outpatients with immunoglobulin light-chain (AL) amyloidosis has not been evaluated...
  22. ncbi request reprint Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
    Paolo G Gobbi
    Medicina Interna e Oncologia Medica and Laboratorio di Ricerche Biotecnologiche, Universita di Pavia, IRCCS Policlinico S Matteo, Piazzale Golgi no 2, 27100 Pavia, Italy
    Clin Cancer Res 11:1786-90. 2005
    ..To verify the reliability of the new criteria for the diagnosis of IgM gammopathies recently proposed by an international panel of experts (Athens, 2002)...
  23. ncbi request reprint [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know]
    Eloisa Arbustini
    Laboratorio di Diagnostica Molecolare, Area Trapiantologica di Ricerca, IRCCS Policlinico San Matteo, Dipartimento di Biochimica, Universita degli Studi, Pavia
    Ital Heart J Suppl 3:590-7. 2002
    ..The fine-needle biopsy of the periumbilical fat is the preferral procedure for amyloid detection and immunocharacterization of amyloid protein. This approach excludes, with a few exceptions, the need of endomyocardial biopsy...
  24. ncbi request reprint Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis
    Eloisa Arbustini
    Amyloid 9:108-14. 2002
    ..Our results demonstrate that amyloid deposits are present in the abdominalfat of patients suspected to have cardiac amyloidosis and that immuno-electron microscopy was able to characterize the amyloid protein in all cases...
  25. ncbi request reprint Amyloidosis: is a cure possible?
    G Merlini
    Amyloidosis Center, Fondazione IRCCS Policlinico San Matteo University of Pavia, Pavia, Italy
    Ann Oncol 19:iv63-6. 2008
  26. pmc Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension?
    L Bernardi
    Department of Internal Medicine, IRCCS S Matteo and University of Pavia, Pavia, Italy
    Heart 88:615-21. 2002
    ..To investigate the possible causes of abnormal blood pressure control in light chain related (primary, AL) amyloidosis...
  27. doi request reprint The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis
    Giovanni Palladini
    Amyloidosis Research and Treatment Center and Department of Biochemistry, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS Policlinico San Matteo and University of Pavia, Viale Golgi 19, Pavia, Italy
    Blood 116:3426-30. 2010
    ..In AL amyloidosis, hs-cTnT is the best baseline prognostic marker. Therapy should be aimed at preventing progression of cardiac biomarkers, whereas NT-proBNP response confers an additional survival benefit...
  28. ncbi request reprint Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
    Giovanni Palladini
    Amyloid Center Biotechnology Research Laboratories, Department of Biochemistry, University Hospital, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
    Blood 103:2936-8. 2004
    ..M-Dex represents a feasible and effective therapeutic option for patients with advanced AL who are ineligible for ASCT...
  29. ncbi request reprint Therapy and management of systemic AL (primary) amyloidosis
    Giovanni Palladini
    Biotechnology Research Laboratories, Centre for Amyloidosis, Department of Biochemistry, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico IRCCS San Matteo, Pavia, Italy
    Swiss Med Wkly 136:715-20. 2006
    ..These new tools can be combined in order to maximise the improvement of organ dysfunction and minimise toxicity, adapting the intervention to each patient...
  30. ncbi request reprint Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families
    Laura Obici
    Biotechnology Research Laboratories, IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy
    Gastroenterology 126:1416-22. 2004
    ....
  31. ncbi request reprint The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
    Giovanni Palladini
    Center for Amyloidosis, Biotechnology Research Laboratories, IRCCS Policlinico San Matteo, Viale Golgi, 19 27100 Pavia, Italy
    Blood 105:2949-51. 2005
    ..The combination of thalidomide and dexamethasone is rapidly effective and may represent a valuable second-line treatment for AL...
  32. ncbi request reprint Utility of biochemical markers in the follow-up of heart transplant recipients
    A Balduini
    Biotechnology Research and Clinical Chemistry Laboratories, Department of Biochemistry, University of Pavia, IRCCS Policlinico S Matteo, Piazzale Golgi 2, 27100 Pavia, Italy
    Transplant Proc 35:3075-8. 2003
    ..Myo and CK-MBm did not show significant changes. cTnT seems to be a potentially useful addition to the EMB results, while SAA and CRP showed variations with respect to EMB grade both in central and peripheral samples...
  33. pmc Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis
    V Perfetti
    Department of Internal Medicine, Internal Medicine and Medical Oncology, University of Pavia, Pavia, Italy
    Am J Pathol 158:1599-603. 2001
    ..In conclusion, our results demonstrate that the t(4;14)(p16.3;q32) translocation is a recurrent genetic lesion in primary amyloidosis...
  34. ncbi request reprint The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies
    G Merlini
    Department of Biochemistry, Biotechnology Research Laboratory, Amyloid Center, University Hospital IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    J Intern Med 255:159-78. 2004
    ..The elucidation of the molecular mechanisms involved in amyloidogenesis is at the basis of the recent blossoming of new, innovative and more effective therapeutic approaches...
  35. ncbi request reprint Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis
    Giovanni Palladini
    Amyloidosis Centre, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
    Amyloid 12:120-6. 2005
    ..We compared the AL patient population observed at a referral center, Mayo Clinic, with that recruited through the Italian network...
  36. ncbi request reprint First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome
    Laura Obici
    University Hospital IRCCS Policlinico San Matteo, Pavia, Italy
    Arthritis Rheum 50:2966-9. 2004
    ..In this patient, 2 mutations in the mevalonate kinase gene were identified, one of which, the leucine-to-arginine substitution at codon 265, is novel...
  37. ncbi request reprint Prognostic factors in symptomatic Waldenstrom's macroglobulinemia
    Giampaolo Merlini
    Research Biotechnology Laboratories, and Internal Medicine and Medical Oncology, IRCCS Policlinico San Matteo, Pavia, Italy
    Semin Oncol 30:211-5. 2003
    ..A prognostic index based on age, hemoglobin, and albumin is capable of identifying various groups of patients with different therapeutic needs...
  38. ncbi request reprint Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I
    Alessia Andreola
    Department of Biochemistry and Centro Interdipartimentale di Biologia Applicata, University of Pavia, via Taramelli 3b, Italy
    J Biol Chem 278:2444-51. 2003
    ....
  39. ncbi request reprint Structure, function and amyloidogenic propensity of apolipoprotein A-I
    Laura Obici
    Centro per lo Studio e la Cura delle Amiloidosi Sistemiche, Laboratorio di Biotecnologie, IRCCS Policlinico San Matteo, Pavia, Italy
    Amyloid 13:191-205. 2006
    ....
  40. ncbi request reprint Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis
    Vittorio Perfetti
    Amyloid Center, IRCCS Policlinico S Matteo P le Golgi 2, 27100 Pavia, Italy
    Haematologica 91:1635-43. 2006
    ..Refined selection of patients suitable for transplantation and personalized adaptation of the doses of melphalan might improve the outcome...
  41. ncbi request reprint The workings of the amyloid diseases
    Vittorio Bellotti
    Center for Amyloidosis, Department of Biochemistry, Biotechnology Research Laboratories, Foundation IRCCS Policlinico San Matteo, Pavia, Italy
    Ann Med 39:200-7. 2007
    ..Due to the pathogenic complexity of amyloid diseases, the integration of several therapeutic interventions involving different critical levels of the amyloidogenic cascade is envisaged...
  42. ncbi request reprint Clinical aspects of systemic amyloid diseases
    Laura Obici
    Amyloid Center, Biotechnology Research Laboratories, IRCCS Policlinico San Matteo, Pavia, Italy
    Biochim Biophys Acta 1753:11-22. 2005
    ....
  43. ncbi request reprint Proteomics of beta2-microglobulin amyloid fibrils
    Monica Stoppini
    Dipartimento di Biochimica, Universita degli Studi di Pavia, via Taramelli 3b, 27100 Pavia, Italy
    Biochim Biophys Acta 1753:23-33. 2005
    ..Other previously reported chemical modifications cannot be excluded, but should involve less than 1-2% of the intact molecule...
  44. pmc Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis
    Sofia Giorgetti
    Department of Biochemistry, University of Pavia Laboratori di Biotecnologie, IRCCS Policlinico San Matteo, via Taramelli 3b, 27100 Pavia, Italy
    Protein Sci 16:343-9. 2007
    ..In contrast, we found no evidence for the presence of DeltaK58-beta2m...
  45. ncbi request reprint Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment
    Vittorio Perfetti
    Internal Medicine and Medical Oncology, Department of Internal Medicine, University of Pavia, IRCCS Policlinico S Matteo, Pavia, Italy
    Blood 100:948-53. 2002
    ..Overusage of just 2 gene segments, 3r and 6a, can thus account for the lambda light-chain overrepresentation typical of this disorder...
  46. pmc Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls
    Gabriella Bianchettin
    Area Infettivologica, Dipartimento di Malattie Infettive, IRCCS Policlinico San Matteo, Via Taramelli 5, 27100 Pavia, Italy
    J Virol 81:4564-71. 2007
    ..Specific changes in HCV envelope sequence distribution are unlikely to be directly involved in the establishment of pathological B-cell monoclonal proliferation...
  47. doi request reprint Proteomics in protein misfolding diseases
    Monica Stoppini
    Department of Biochemistry, University of Pavia, Pavia, Italy
    Clin Chem Lab Med 47:627-35. 2009
    ..We present the developments in the field of proteomics applied to systemic amyloidoses, and discuss the perspectives opened in the study of these diseases...
  48. doi request reprint Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis
    Giovanni Montagna
    IRCCS Fondazione Salvatore Maugeri, Pavia, Italy
    Amyloid 16:115-21. 2009
    ....
  49. ncbi request reprint Lysozyme: a paradigmatic molecule for the investigation of protein structure, function and misfolding
    Giampaolo Merlini
    Biotechnology Research Laboratory, University Hospital IRCCS Policlinico San Matteo, Department of Biochemistry, University of Pavia, P le Golgi, 2, 27100 Pavia, Italy
    Clin Chim Acta 357:168-72. 2005
    ..Four amyloidogenic mutations have been identified and an apparently non-amyloidogenic polymorphism has been recently described...
  50. pmc Insights into the regulation of immunoglobulin light chain gene rearrangements via analysis of the kappa light chain locus in lambda myeloma
    Vittorio Perfetti
    Internal Medicine and Medical Oncology, IRCCS Policlinico S Matteo University of Pavia, Pavia, Italy
    Immunology 112:420-7. 2004
    ..These findings provide insights into the regulation of light chain rearrangements and support the view that B cells may occasionally undergo sequential light chain rearrangements after the onset of somatic hypermutation...
  51. ncbi request reprint Doxorubicin and congo red effectiveness on prion infectivity in golden Syrian hamster
    Manuel Corato
    Laboratory of Experimental Neurobiology, Neurological Institute IRCCS C Mondino, Pavia, Italy
    Anticancer Res 29:2507-12. 2009
    ..05). Doxorubicin and Congo Red effects do not depend upon interaction with PrP amyloid material...
  52. ncbi request reprint Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine
    Giovanni Palladini
    Center for Amyloidosis, Biotechnology Research Laboratories, Department of Biochemistry, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy
    Clin Chem 55:499-504. 2009
    ....
  53. ncbi request reprint Obstructive intramural coronary amyloidosis: a distinct phenotype of cardiac amyloidosis that can cause acute heart failure
    Michele Pasotti
    Department of Cardiology, I R C C S Policlinico San Matteo, Pavia, Italy
    Eur Heart J 27:1810. 2006
  54. ncbi request reprint Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins
    Valentina Navazza
    Department of Internal Medicine, Clinica Medica I, Fondazione IRCCS Policlinico San Matteo University of Pavia, P le Golgi 2, 27100 Pavia, Italy
    Mol Immunol 45:1519-24. 2008
    ..In particular, a rare replacement of a polar residue with proline is shared at the beginning of the VH complementarity-determining region 2, and this residue might be involved in intermolecular contacts...
  55. ncbi request reprint Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient
    Stefania Mantovani
    Experimental Immunology Laboratory, IRCCS Maugeri Foundation, Pavia, Italy
    J Invest Dermatol 121:308-14. 2003
    ..These data, together with the skin-homing potential of the clones, directly point to the in vivo pathogenic role of melanocyte-specific cytotoxic T lymphocytes in vitiligo...
  56. pmc Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue
    Francesca Lavatelli
    Amyloid Treatment and Research Program, Boston, Massachusetts, USA
    Mol Cell Proteomics 7:1570-83. 2008
    ....
  57. doi request reprint Gender-related risk of myocardial involvement in systemic amyloidosis
    Claudio Rapezzi
    Institute of Cardiology, University of Bologna, Bologna, Italy
    Amyloid 15:40-8. 2008
    ..In conclusion, these findings raise the hypothesis that some biological characteristic associated with female gender protects against myocardial involvement in familial ATTR...
  58. ncbi request reprint Genetic microheterogeneity of human transthyretin detected by IEF
    Klaus Altland
    Institut fur Humangenetik, Justus Liebig Universitat, Giessen, Germany
    Electrophoresis 28:2053-64. 2007
    ..All types of amyloidogenic mutations affected the stability of TTR tetramers...
  59. ncbi request reprint Eprodisate for the treatment of renal disease in AA amyloidosis
    Laura M Dember
    Boston University School of Medicine, Boston, MA 02118, USA
    N Engl J Med 356:2349-60. 2007
    ....
  60. ncbi request reprint Bortezomib in the treatment of AL amyloidosis: targeted therapy?
    Roberto Sitia
    Haematologica 92:1302-7. 2007
  61. ncbi request reprint Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis
    Giovanni Palladini
    Blood 110:787-8. 2007
  62. ncbi request reprint How we treat Waldenström's macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Greece
    Haematologica 90:117-25. 2005
    ....
  63. ncbi request reprint Autoantibody activity in Waldenstrom's macroglobulinemia
    Marvin J Stone
    Baylor Charles A Sammons Cancer Center, 3535 Worth Street, Dallas, TX 75246, USA
    Clin Lymphoma 5:225-9. 2005
    ..Study of the antigens reacting with monoclonal IgMs may provide further insight into the pathogenesis of WM...
  64. ncbi request reprint Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis
    Bouke P C Hazenberg
    Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands
    Amyloid 14:133-40. 2007
    ..Amyloid A protein quantification in fat tissue is a new immunochemical method for detecting AA amyloidosis, a rare but serious disease. The objective was to assess diagnostic performance in clinical AA amyloidosis...
  65. ncbi request reprint Hereditary amyloidosis
    Giovanni Palladini
    N Engl J Med 347:1206-7; author reply 1206-7. 2002
  66. ncbi request reprint Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Robert A Kyle
    Mayo Clinic, Rochester, MN, USA
    Semin Oncol 30:116-20. 2003
    ..However, the panel felt that current data are inadequate to support the use of any prognostic marker to select the timing and type of therapy, and called for studies on the application of prognostic markers in WM...
  67. ncbi request reprint Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia
    Eva Kimby
    Karolinska University Hospital, Stockholm, Sweden
    Clin Lymphoma Myeloma 6:380-3. 2006
    ..The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease...
  68. ncbi request reprint Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL
    Giovanni Palladini
    Biotechnology Research Laboratories IRCCS Policlinico San Matteo, Piazzale Golgi 19, 27100 Pavia, Italy
    Blood 107:3854-8. 2006
    ..Cardiac function in AL can rapidly improve due to a reduction of the circulating amyloidogenic precursor, despite the amount of cardiac amyloid deposits remaining apparently unaltered, as measured by echocardiography...
  69. ncbi request reprint Guidelines for the analysis of Bence Jones protein
    Mariastella Graziani
    Clinical Chemistry Laboratory, Ospedale Civile Maggiore, Verona, Italy
    Clin Chem Lab Med 41:338-46. 2003
    ..The physiology of immunoglobulins and the clinical relevance of BJP are illustrated in the two appendices to this paper...
  70. ncbi request reprint IX International Symposium on Amyloidosis, July 15-21, 2001, Budapest, Hungary
    Jean D Sipe
    Tissue Engineering Study Section, Center for Scientific Review, National Institutes of Health, Bethesda, MD 20892 7814, USA
    Amyloid 9:52-65. 2002
  71. ncbi request reprint Amyloid fibril protein nomenclature -- 2002
    Per Westermark
    Amyloid 9:197-200. 2002
  72. ncbi request reprint A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL)
    Morie A Gertz
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Amyloid 9:24-30. 2002
    ..4'-Iodo-4'-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits. A multicenter study attempted to develop a dosing schedule to confirm those results...
  73. ncbi request reprint Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals
    Gianvico Melzi d'Eril
    Clin Chem 49:1554-5. 2003
  74. ncbi request reprint Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease"
    Ersilia De Lorenzi
    Dipartimento di Chimica Farmaceutica, Universita di Pavia, Italy
    Curr Med Chem 11:1065-84. 2004
    ....
  75. ncbi request reprint Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system
    Luca Baldini
    Unità Operativa Ematologia 1, Dipartimento di Ematologia e Oncologia, Ospedale Maggiore, I R C C S, Milano, Italy
    J Clin Oncol 23:4662-8. 2005
    ....
  76. ncbi request reprint 4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters
    Isabel Cardoso
    Amyloid Unit, Institute for Molecular and Cell Biology, University of Porto, Portugal
    FASEB J 17:803-9. 2003
    ....
  77. ncbi request reprint Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: an atomic force microscopy study
    Annalisa Relini
    National Institute for the Physics of Matter and Department of Physics, University of Genoa, Via Dodecaneso 33, I 16146, Genoa, Italy
    Biochim Biophys Acta 1690:33-41. 2004
    ..4+/-0.4 and 5.1+/-0.5 nm, measured under liquid) and is compatible with the protofilament expected diameter, suggesting that globules may represent protofilament precursors...
  78. ncbi request reprint Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition
    A Myron Johnson
    Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC 27410, USA
    Clin Chem Lab Med 45:419-26. 2007
    ..In addition to these caveats, assays for TTR have a relatively high level of uncertainty ("imprecision"). Clinical evaluation--history and physical examination--should remain the mainstay of nutritional assessment...
  79. ncbi request reprint Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia
    Steven P Treon
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute LG102, 44 Binney Street, Boston, MA 02115, USA
    Blood 107:3442-6. 2006
    ....
  80. ncbi request reprint Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis
    Gina Gregorini
    Division of Nephrology, Spedali Civili, Brescia, Italy
    J Am Soc Nephrol 16:3680-6. 2005
    ..Patients who present with familial tubulointerstitial nephritis associated with liver disease require a high index of suspicion for apolipoprotein A-I amyloidosis...
  81. ncbi request reprint Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis
    Per Westermark
    Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
    Amyloid 12:1-4. 2005
    ..Synthetic fibrils with amyloid properties are best named 'amyloid-like'. With increasing knowledge, however, the borders between different protein aggregates tend to become less sharp...
  82. ncbi request reprint Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004
    Morie A Gertz
    Dysproteinemia Clinic, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 79:319-28. 2005
    ..We report criteria that centers can now use to define organ involvement and uniform response criteria for reporting outcomes in patients with light-chain AL...
  83. ncbi request reprint A primer of amyloid nomenclature
    Per Westermark
    Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden
    Amyloid 14:179-83. 2007
    ..All amyloid types are today preferably named by their major fibril protein. This makes a simple and rational nomenclature for the increasing number of amyloid disorders known in humans and animals...
  84. ncbi request reprint Autologous stem cell and kidney transplantation for primary amyloidosis associated with ESRD: which should come first?
    Giampaolo Merlini
    Am J Transplant 5:1585-6. 2005
  85. pmc Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen
    Sofia Giorgetti
    Dipartimento di Biochimica, Universita degli Studi di Pavia, via Taramelli 3 b 27100 Pavia, Italy
    Protein Sci 14:696-702. 2005
    ....
  86. doi request reprint The controlling roles of Trp60 and Trp95 in beta2-microglobulin function, folding and amyloid aggregation properties
    Gennaro Esposito
    Department of Biomedical Science and Technology, University of Udine, Piazzale Kolbe 4, 33100 Udine, Italy
    J Mol Biol 378:887-97. 2008
    ....
  87. doi request reprint Sjögren's syndrome and localized nodular cutaneous amyloidosis: coincidence or a distinct clinical entity?
    Jiska M Meijer
    University of Groningen, Groningen, The Netherlands
    Arthritis Rheum 58:1992-9. 2008
    ..To report 8 patients with Sjögren's syndrome (SS) and localized nodular cutaneous amyloidosis and to examine serologic and immunohistologic findings that may link the 2 diseases...